Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.
暂无分享,去创建一个
R. Greil | R. Hájek | H. Ludwig | A. Dmoszyńska | J. Harousseau | T. Masszi | O. Shpilberg | C. Enny | I. Špička | A. Cakana | Huaibao Feng | H. Velde | L. Viterbo